About: Taspoglutide

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche. Initially, phase II trials reported it was effective and well tolerated. Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)

Property Value
dbo:abstract
  • Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche. Initially, phase II trials reported it was effective and well tolerated. Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.) In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2022 no new trials have been registered since 2010. (en)
dbo:casNumber
  • 275371-94-3
dbo:fdaUniiCode
  • 2PHK27IP3B
dbo:kegg
  • D09723
dbo:pubchem
  • 56842233
dbo:wikiPageID
  • 21066639 (xsd:integer)
dbo:wikiPageLength
  • 4571 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1110021267 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:bioavailability
  • N/A (en)
dbp:c
  • 152 (xsd:integer)
dbp:casNumber
  • 275371 (xsd:integer)
dbp:chemspiderid
  • 32819947 (xsd:integer)
dbp:date
  • September 2022 (en)
dbp:h
  • 232 (xsd:integer)
dbp:kegg
  • D09723 (en)
dbp:n
  • 40 (xsd:integer)
dbp:o
  • 45 (xsd:integer)
dbp:pubchem
  • 56842233 (xsd:integer)
dbp:reason
  • incidence is normally used only in the singular form, perhaps incidence, incidents, or instances was intended (en)
dbp:routesOfAdministration
dbp:unii
  • 2 (xsd:integer)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 470477813 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche. Initially, phase II trials reported it was effective and well tolerated. Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.) (en)
rdfs:label
  • Taspoglutide (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License